Literature DB >> 497089

Biliary excretion of erythromycin after parenteral administration.

P Chelvan, J M Hamilton-Miller, W Brumfitt.   

Abstract

1 The biliary excretion of erythromycin has been studied following parenteral administration in 23 patients. 2 Mean bile levels of the drug were approximately ten times higher than corresponding serum concentrations 1 h after i.v. (erythromycin lactobionate) and i.m. (erythromycin ethylsuccinate) injection. 3 Thus, unlike many antimicrobial agents, these compounds are well concentrated in the bile.

Entities:  

Mesh：

Substances：

Year:  1979        PMID： 497089      PMCID： PMC1429793          DOI： 10.1111/j.1365-2125.1979.tb01007.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


  7 in total

1.  Gallbladder bile concentrations of the major antibiotics following intravenous administration.

Authors:  E J PULASKI; M H FUSILLO
Journal:  Surg Gynecol Obstet       Date:  1955-05

2.  Factors affecting the absorption and biliary excretion of erythromycin and two of its derivatives in humans.

Authors:  J B HAMMOND; R S GRIFFITH
Journal:  Clin Pharmacol Ther       Date:  1961 May-Jun       Impact factor: 6.875

3.  [Biliary elimination of antibiotics].

Authors:  M LEVRAT; R BRETTE; J THIVOLET; M CARRAZ
Journal:  Rev Int Hepatol       Date:  1957

4.  Excretion of erythromycin and its enhanced activity in urine against gram-negative bacilli with alkalinization.

Authors:  L D Sabath; D A Gerstein; P B Loder; M Finland
Journal:  J Lab Clin Med       Date:  1968-12

5.  Transient bacteremia and endocarditis prophylaxis. A review.

Authors:  E D Everett; J V Hirschmann
Journal:  Medicine (Baltimore)       Date:  1977-01       Impact factor: 1.889

6.  The biliary excretion of erythromycin (ilotycin).

Authors:  J R TWISS; W V BERGER; L GILLETTE; A R ARONSON; L SIEGEL
Journal:  Surg Gynecol Obstet       Date:  1956-03

7.  Antibacterial activity of 2'-esters of erythromycin.

Authors:  P L Tardrew; J C Mao; D Kenney
Journal:  Appl Microbiol       Date:  1969-08
  7 in total
  11 in total

1.  Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein.

Authors:  R B Kim; C Wandel; B Leake; M Cvetkovic; M F Fromm; P J Dempsey; M M Roden; F Belas; A K Chaudhary; D M Roden; A J Wood; G R Wilkinson
Journal:  Pharm Res       Date:  1999-03       Impact factor: 4.200

Review 2.  Clinical pharmacokinetic properties of the macrolide antibiotics. Effects of age and various pathophysiological states (Part II).

Authors:  P Periti; T Mazzei; E Mini; A Novelli
Journal:  Clin Pharmacokinet       Date:  1989-05       Impact factor: 6.447

3.  Pharmacokinetics of erythromycin in patients with severe cirrhosis. Respective influence of decreased serum binding and impaired liver metabolic capacity.

Authors:  J Barre; A Mallat; J Rosenbaum; L Deforges; G Houin; D Dhumeaux; J P Tillement
Journal:  Br J Clin Pharmacol       Date:  1987-06       Impact factor: 4.335

Review 4.  Antibiotics in the treatment of biliary infection.

Authors:  J S Dooley; J M Hamilton-Miller; W Brumfitt; S Sherlock
Journal:  Gut       Date:  1984-09       Impact factor: 23.059

5.  Therapeutic doses of erythromycin esteolate is not cholestatic in rats in vivo.

Authors:  I Fiebiger; M S Anwer; D Hegner
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1983-05       Impact factor: 3.000

Review 6.  Adverse effects of macrolide antibacterials.

Authors:  P Periti; T Mazzei; E Mini; A Novelli
Journal:  Drug Saf       Date:  1993-11       Impact factor: 5.606

7.  Pharmacokinetic advantages of erythromycin estolate over ethylsuccinate as determined by high-pressure liquid chromatography.

Authors:  D Croteau; M G Bergeron; M LeBel
Journal:  Antimicrob Agents Chemother       Date:  1988-04       Impact factor: 5.191

8.  Gastrointestinal side effects after intravenous erythromycin lactobionate.

Authors:  K M Downey; D M Chaput de Saintonge
Journal:  Br J Clin Pharmacol       Date:  1986-03       Impact factor: 4.335

9.  Structural and functional implications of the interaction between macrolide antibiotics and bile acids.

Authors:  Simon Glanzer; Sergio A Pulido; Sarah Tutz; Gabriel E Wagner; Manfred Kriechbaum; Nina Gubensäk; Jovana Trifunovic; Markus Dorn; Walter M F Fabian; Predrag Novak; Joachim Reidl; Klaus Zangger
Journal:  Chemistry       Date:  2015-02-05       Impact factor: 5.236

Review 10.  Macrolides: From Toxins to Therapeutics.

Authors:  Kiersten D Lenz; Katja E Klosterman; Harshini Mukundan; Jessica Z Kubicek-Sutherland
Journal:  Toxins (Basel)       Date:  2021-05-12       Impact factor: 4.546
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.